Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis

Respiratory Medicine

Volumn 101, Issue 10, 2007, Pages 2199-2206

  Andersen, Grethe Neumann ^a   Nilsson, Kenneth ^a   Pourazar, Jamshid ^a   Hackett, Tillie Louise ^b   Kazzam, Elsadig ^a,c   Blomberg, Anders ^a   Waldenström, Anders ^c   Warner, Jane ^b   Rantapää Dahlqvist, Solbritt ^a   Mincheva Nilsson, Lucia ^a   Sandström, Thomas ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c Eskilstuna County Hospital   (Sweden)

Author keywords

Bronchoalveolar lavage; Interstitial lung disease; MMP9; Systemic sclerosis

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN CELL; INTERSTITIAL LUNG DISEASE; LUNG CAPACITY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; SYSTEMIC SCLEROSIS;

ADULT; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; HUMANS; LEUKOCYTE COUNT; LUNG DISEASES, INTERSTITIAL; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEUTROPHILS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 34548305128     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.04.019     Document Type: Article

References (45)

1. D'Angelo W.A., Fries J.F., Masi A.T., and Shulman L.E. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46 (1969) 428-440
2. Steen V.D., Conte C., Owens G., and Medsger Jr. T.A. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37 (1994) 1283-1289
3. Medsger Jr. T.A., Masi A.T., Rodnan G.P., Benedek T.G., and Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 75 (1971) 69-76
4. Devenyi K., and Czirjak L. High resolution computed tomography for the evaluation of lung involvement in 101 patients with scleroderma. Clin Rheumatol 14 (1995) 633-640
5. Bouros D., Wells A.U., Nicholson A.G., Colby T.V., Polychronopoulos V., Pantelidis P., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165 (2002) 1581-1586
6. Wells A.U., Hansell D.M., Corrin B., Harrison N.K., Goldstraw P., Black C.M., et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 47 (1992) 738-742
7. Crestani B., Seta N., Palazzo E., Rolland C., Venembre P., Dehoux M., et al. Interleukin-8 and neutrophils in systemic sclerosis with lung involvement. Am J Respir Crit Care Med 150 (1994) 1363-1367
8. Chanez P., Lacoste J.-Y., Guillot B., Giron J., Barneon G., Enander I., et al. Mast cells' contribution to the fibrosing alveolitis of the scleroderma lung. Am Rev Respir Dis 147 (1993) 1497-1502
9. Nagase H. Matrix metalloproteinases. In: Hooper N.M. (Ed). Zinc metalloproteinases in health and disease (1996), Taylor & Francis, London 153-204
10. Corbel M., Theret N., Caulet-Maugendre S., Germain N., Lagente V., Clement B., et al. Repeated endotoxin exposure induces interstitial fibrosis associated with enhanced gelatinase (MMP-2 and MMP-9) activity. Inflamm Res 50 (2001) 129-135
11. Suga M., Iyonaga K., Okamoto T., Gushima Y., Miyakawa H., Akaike T., et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 162 (2000) 1949-1956
12. Beeh K.M., Beier J., Kornmann O., and Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Resp Med 97 (2003) 634-639
13. Finlay G.A., Russell K.J., McMahon K.J., D`arcy E.M., Masterson J.B., FitzGerald M.X., et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 52 (1997) 502-506
14. Segura-Valdez L., Pardo A., Gaxiola M., Uhal B.D., Becerril C., and Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 117 (2000) 684-694
15. Russell R.E.K., Culpitt S.V., DeMatos C., Donelly L., Smith M., Wiggins J., et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 26 (2002) 602-609
16. Ricou B., Nicod L., Lacraz S., Welgus H.G., Suter P.M., and Dayer J.-M. Matrix metalloproteinases and TIMP an acute respiratory distress syndrome. Am J Respir Crit Care Med 154 (1996) 346-352
17. Torii K., Iida K.-I., Miyazaki Y., Saga S., Kondoh Y., Taniguchi H., et al. Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am J Respir Crit Care Med 155 (1997) 43-46
18. Mautino G., Henriquet C., Jaffuel D., Bousquet J., and Capony F. Tissue inhibitor of metalloproteinase-1 levels in bronchoalveolar lavage fluid from asthmatic subjects. Am J Respir Crit Care Med 160 (1999) 324-330
19. Cataldo D.D., Gueders M., Munaut C., Rocks N., Bartsch P., Foidart J.-M., et al. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases mRNA transcripts in the bronchial secretions of asthmatics. Lab Invest 84 (2004) 418-424
20. Cowland J.B., and Borregaard N. The individual regulation of granule protein mRNA during neutrophil maturation explains the heterogeneity of neutrophil granules. J Leukocyte Biol 66 (1999) 989-995
21. Schwingschackl A., Duszyk M., Brown N., and Moqbel R. Human eosinophils release matrix metalloproteinase-9 on stimulation with TNF-alpha. J Allergy Clin Immunol 104 (1999) 983-989
22. Masure S., Proost P., van Damme J., and Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur J Biochem 198 (1991) 391-398
23. Baram D., Vaday G.G., Salamon P., Drucker I., Hershkoviz R., and Mekori Y.A. Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol 167 (2001) 4008-4016
24. Weeks B.S., Schnaper H.W., Handy M., Holloway E., and Kleinman H.K. Human T lymphocytes synthesise the 92 kDa type IV collagenase (gelatinase B). J Cell Physiol 157 (1993) 644-649
25. Ogata Y., Enghild J.J., and Nagase H. Matrix metalloproteinase 3 (stromelysisn) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267 (1992) 21712-21719
26. Frank B.T., Rossall J.C., Caughey G.H., and Fang K.C. Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by alpha-chymase. J Immunol 166 (2001) 2783-2792
27. Kikuchi K., Kadono T., Furue M., and Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 108 (1997) 281-284
28. Southcott A.M., Jones K.P., Li D., Majumdar S., Cambrey A.D., Pantelidis P., et al. Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med 151 (1995) 1604-1612
29. Silver R.M., Metcalf J.F., Stanley J.H., and LeRoy E.C. Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum 27 (1984) 1254-1262
30. Gustafsson R., Fredens K., Nettelbladt O., and Hällgren R. Eosinophil activation in systemic sclerosis. Arthritis Rheum 34 (1991) 414-422
31. Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23 (1980) 581-590
32. LeRoy E.C., Black C., Fleishmajer R., Jablonska S., Krieg T., Medsger Jr. T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15 (1988) 202-205
33. Alarcon-Segovia D., and Cardiel M.H. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 16 (1989) 328-334
34. 2 on the airways of healthy subjects. Am J Respir Crit Care Med 156 (1997) 418-424
35. Bolster M.B., Ludwicka A., Sutherland S.E., Strange C., and Silver R.M. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 40 (1997) 743-751
36. Ramos C., Montano M., Garcia-Alvarez J., Ruiz V., Uhal B.D., Selman M., et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 24 (2001) 591-598
37. Steen V.D., Graham G., Conte C., Owens G., and Medsger Jr. T.A. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 35 (1992) 765-770
38. Stupi A.M., Steen V.D., Owens G.R., Barnes E.L., Rodnan G.P., and Medsger Jr. T.A. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29 (1986) 515-524
39. Dell'aica I, Niero R, Piazza F, Cabrelle A, Sartor L, Colalto C, et al. Hyperforin blocks neutrophil activation of MMP-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis. J Pharmacol Exp Ther, 2007, February 8 [Epub ahead of print].
40. Van den Steen P.E., Proost P., Wuyts A., Van Damme J., and Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 96 (2000) 2673-2681
41. Schönbeck U., Mach F., and Libby P. Generation of biologically active IL-1beta by matrix metalloproteinases: a novel caspase-1 independent pathway of IL-1beta processing. J Immunol 161 (1998) 3340-3346
42. Van den Steen P.E., Proost P., Grillet B., Brand D.D., Kang A.H., van Damme J., et al. Cleavage of denatured natural collagen type II by neutrophil collagenase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB J 16 (2002) 379-389
43. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., Van den Oord J., et al. Resistance of young gelatinase-B resistant mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 104 (1999) 1507-1515
44. Corbel M., Caulet-Maugendre S., Germain N., Molet S., Lagente V., and Boichot E. Inhibition of bleomycin-induced pulmonary fibrosis by the matrix metalloproteinase inhibitor batimastat. J Pathol 193 (2001) 538-545
45. Brown P.D. Ongoing trials with metalloproteinase inhibitors. Exp Opin Drugs 9 (2000) 2167-2177